[go: up one dir, main page]

CA3267555A1 - Compositions d'analogues de n-n-diméthyltryptamine (dmt) et de dmt, leurs procédés de fabrication et leurs procédés d'utilisation - Google Patents

Compositions d'analogues de n-n-diméthyltryptamine (dmt) et de dmt, leurs procédés de fabrication et leurs procédés d'utilisation

Info

Publication number
CA3267555A1
CA3267555A1 CA3267555A CA3267555A CA3267555A1 CA 3267555 A1 CA3267555 A1 CA 3267555A1 CA 3267555 A CA3267555 A CA 3267555A CA 3267555 A CA3267555 A CA 3267555A CA 3267555 A1 CA3267555 A1 CA 3267555A1
Authority
CA
Canada
Prior art keywords
dmt
methods
dimethyltryptamine
making
analog compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3267555A
Other languages
English (en)
Inventor
Srinivas G Rao
Glenn Short
Majed Fawaz
Prerak Patel
Santnu Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Atai Therapeutics Inc
Original Assignee
Atai Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US17/974,443 external-priority patent/US20230136824A1/en
Application filed by Atai Therapeutics Inc filed Critical Atai Therapeutics Inc
Publication of CA3267555A1 publication Critical patent/CA3267555A1/fr
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3267555A 2022-10-26 2023-10-26 Compositions d'analogues de n-n-diméthyltryptamine (dmt) et de dmt, leurs procédés de fabrication et leurs procédés d'utilisation Pending CA3267555A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17/974,443 US20230136824A1 (en) 2021-04-26 2022-10-26 N-n-dimethyltryptamine (dmt) and dmt analog compositions, methods of making, and methods of use thereof
PCT/US2023/077879 WO2024092106A2 (fr) 2022-10-26 2023-10-26 Compositions d'analogues de n-n-diméthyltryptamine (dmt) et de dmt, leurs procédés de fabrication et leurs procédés d'utilisation

Publications (1)

Publication Number Publication Date
CA3267555A1 true CA3267555A1 (fr) 2024-05-02

Family

ID=90832092

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3267555A Pending CA3267555A1 (fr) 2022-10-26 2023-10-26 Compositions d'analogues de n-n-diméthyltryptamine (dmt) et de dmt, leurs procédés de fabrication et leurs procédés d'utilisation

Country Status (6)

Country Link
EP (1) EP4608395A2 (fr)
AR (1) AR130877A1 (fr)
AU (1) AU2023367107A1 (fr)
CA (1) CA3267555A1 (fr)
TW (1) TW202423415A (fr)
WO (1) WO2024092106A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3182156A1 (fr) 2020-05-08 2021-11-11 Psilera Inc. Nouvelles compositions de matiere et compositions pharmaceutiques
EP4347562A4 (fr) 2021-05-25 2025-04-30 ATAI Therapeutics, Inc. Nouveaux sels de n,n-diméthyltryptamine et nouvelles formes de sel cristallin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3146050A1 (fr) * 2019-07-04 2021-01-07 Sw Holdings, Inc. Compositions de dosage et procedes d'utilisation de composes psychedeliques
US20210015738A1 (en) * 2019-07-17 2021-01-21 Concept Matrix Solutions Oral dissolvable film containing psychedelic compound
CA3182156A1 (fr) * 2020-05-08 2021-11-11 Psilera Inc. Nouvelles compositions de matiere et compositions pharmaceutiques
BR112022025306A2 (pt) * 2020-06-12 2023-02-28 Beckley Psytech Ltd Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina
CA3192617A1 (fr) * 2020-09-20 2022-03-24 Matthew BAGGOTT Compositions de tryptamine avantageuses pour troubles mentaux ou amelioration mentale
MX2023012651A (es) * 2021-04-26 2023-11-06 Atai Therapeutics Inc Novedosas composiciones y metodos de n,n-dimetiltriptamina.

Also Published As

Publication number Publication date
AR130877A1 (es) 2025-01-29
AU2023367107A1 (en) 2025-03-27
WO2024092106A2 (fr) 2024-05-02
TW202423415A (zh) 2024-06-16
EP4608395A2 (fr) 2025-09-03
WO2024092106A3 (fr) 2024-06-06

Similar Documents

Publication Publication Date Title
CA3267555A1 (fr) Compositions d'analogues de n-n-diméthyltryptamine (dmt) et de dmt, leurs procédés de fabrication et leurs procédés d'utilisation
EP3965780A4 (fr) Compositions oligonucléotidiques et leurs procédés d'utilisation
EP3976638A4 (fr) Compositions d'il-2 et leurs méthodes d'utilisation
EP4313003A4 (fr) Compositions de polynucléotides, formulations associées et leurs méthodes d'utilisation
IL299108A (en) Analogues of hydroxynoractamine, preparations including them and methods of using them
EP4081231A4 (fr) Compositions comprenant des microbes et leurs procédés d'utilisation et de fabrication
CA3262480A1 (fr) Compositions ciblant des protéines d'activation des fibroblastes et leurs méthodes d'utilisation
IL308221A (en) Preparations and methods for treating depression
IL308041A (en) Collagen compositions and methods of using them
EP4376846A4 (fr) Compositions bioactives et procédés d'utilisation de celles-ci
IL318328A (en) Compositions comprising multi-agonist peptides and methods for making and using them
EP4204004A4 (fr) Compositions anti-idiotype et procédés d'utilisation associés
EP4298076A4 (fr) Compositions céramiques et leurs procédés d'utilisation
EP4381022A4 (fr) Compositions et leurs procédés d'utilisation
GB202319843D0 (en) CAS13-based compositions and methods of use thereof
IL312928A (en) Complement Factor B Modulating Preparations and Methods for Using Them
CA3259912A1 (fr) Compositions de tirzepatide et leur utilisation
IL314226A (en) Designed cytokine compositions and methods of use
IL313980A (en) The compositions containing the alpha-Factor Perro sequence and uses thereof
IL315862A (en) Angiotensinogen modulators and methods of using them
CA3257282A1 (fr) Compositions de collagène et leurs procédés d'utilisation
MX2024000801A (es) Composiciones para el cuidado oral.
GB202215745D0 (en) Compositions and methods and uses thereto
IL314293A (en) Olanzapine, its compounds and methods of using it
IL323920A (en) MAPT modulators and methods of using them